French biotech firm TheraVectys plans for HK IPO: Bloomberg

French biotechnology company TheraVectys is considering a Hong Kong initial public offering this year that could raise several hundred million US dollars, in what would be a rare listing in one of the world's largest IPO markets by a non-Chinese biotech firm, Bloomberg reported.

The company is engaging with advisers on this potential offering, but no final decision has been made, the report said.

The Paris- and US-based company, a spun-off unit from the Institut Pasteur, focuses on immunotherapy businesses.

It's backed by Tethys Invest SAS, the investment firm of L'Oreal SA heiress Francoise Bettencourt Meyers and her family. 

The biotech firm develops an extensive pipeline of vaccine candidates to drive the widespread treatment and prevention of cancer and infectious diseases.